dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Arrambide García, Georgina |
dc.contributor.author | Llaneza González, Miguel Ángel |
dc.contributor.author | Fernández-Díaz, Eva |
dc.contributor.author | Moreno Torres, Irene |
dc.contributor.author | Meca-Lallana, Virginia |
dc.contributor.author | Costa-Frossard França, Lucienne |
dc.date.accessioned | 2022-04-06T06:38:46Z |
dc.date.available | 2022-04-06T06:38:46Z |
dc.date.issued | 2021-06-24 |
dc.identifier.citation | Arrambide G, Llaneza-González MA, Costa-Frossard França L, Meca-Lallana V, Díaz EF, Moreno-Torres I, et al. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry. Neurol Neuroimmunol Neuroinflamm. 2021 Jun 24;8(5):e1024. |
dc.identifier.issn | 2332-7812 |
dc.identifier.uri | https://hdl.handle.net/11351/7306 |
dc.description | Esclerosi múltiple; Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV |
dc.description.sponsorship | This work was funded by the Spanish Society of Neurology for the writing, editorial assistance, statistical analysis and the Article Processing Charge. Other contributions related to financial support for writing, statistical analysis, and editorial assistance were supported by Biogen, Bristol-Myers Squibb, Merck, Roche, Sanofi, and Teva. |
dc.language.iso | eng |
dc.publisher | Lippincott Williams & Wilkins |
dc.relation.ispartofseries | Neurology® neuroimmunology & neuroinflammation;8(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Esclerosi múltiple - Tractament |
dc.subject | Medicaments immunosupressors - Ús terapèutic - Efectes secundaris |
dc.subject | COVID-19 (Malaltia) - Epidemiologia |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Multiple Sclerosis |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Immunosuppressive Agents |
dc.title | SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1212/NXI.0000000000001024 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | esclerosis múltiple |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | inmunosupresores |
dc.relation.publishversion | https://doi.org/10.1212/NXI.0000000000001024 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Arrambide G] Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Llaneza-González MA] Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain. [Costa-Frossard França L] Hospital Universitario Ramón y Cajal, Madrid, Spain. [Meca-Lallana V] Hospital Universitario de la Princesa, Madrid, Spain. [Díaz EF] Complejo Hospitalario Universitario de Albacete, Albacete, Spain. [Moreno-Torres I] Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain |
dc.identifier.pmid | 34168057 |
dc.identifier.wos | 000711825500024 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |